My research focuses on evaluating novel agents in the treatment of acute leukemias and related disorders such as myelodysplastic syndromes. I have a number of investigator initiated clinical studies focusing on using small molecule inhibitors and hypomethylating agents to target intracellular pathways mediating chemotherapy drug resistance in acute myeloid leukemia. These include correlative studies to attempt to better understand these mechanisms. I am also involved with a number of international multicentre studies testing novel agents, both alone and in combination, in leukemias.
My research also involves evaluating outcomes with standard treatment regimens in acute myeloid and lymphoblastic leukemia, in order to identify important prognostic factors, as well as protocol development focusing on improving outcomes and treatment related toxicities.